8-K: Leap Therapeutics Faces Nasdaq Delisting Risk After Share Price Drops Below $1.00

Leap Therapeutics receives notification from Nasdaq regarding non-compliance with minimum share price requirement, triggering a potential delisting process.

Summary

• Leap Therapeutics received a notification from Nasdaq on March 12, 2025, because its common stock closing bid price fell below $1.00 for 30 consecutive business days.
• This violates Nasdaq Listing Rule 5550(a)(2).
• The notification does not immediately affect the listing or trading of Leap Therapeutics' shares.
• Leap Therapeutics has until September 8, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• An additional 180-day compliance period may be available if the company meets other listing requirements and notifies Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split.
• Leap Therapeutics intends to monitor its stock price and consider options for regaining compliance, but there is no guarantee it will succeed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance. While the company has options, the situation presents a significant risk.

Positives

• The notification is a deficiency notice, not an immediate delisting.
• Leap Therapeutics has a 180-day period to regain compliance.
• The company may be eligible for an additional 180-day compliance period.

Negatives

• Leap Therapeutics' common stock has traded below $1.00 for 30 consecutive business days.
• There is no guarantee that the company will be able to regain compliance with Nasdaq listing rules.
• Delisting from the Nasdaq Capital Market could negatively impact the company's stock price and investor confidence.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• A reverse stock split, while potentially increasing the share price, could be viewed negatively by investors.
• Continued low stock price could limit the company's ability to raise capital.

Future Outlook

Leap Therapeutics intends to monitor its stock price and consider plans for regaining compliance with Nasdaq listing rules, including a potential reverse stock split, but there is no assurance it will be successful.

Management Comments

• The Company intends to monitor closely the closing bid price of its common stock and to consider plans for regaining compliance with Rule 5550(a)(2).

Industry Context

Many small-cap biotech companies face challenges in maintaining share price compliance, especially during periods of market volatility or negative clinical trial results. Delisting can significantly impact a company's access to capital and investor base.

Comparison to Industry Standards

• Other biotech companies facing similar delisting notices include [hypothetical company A] and [hypothetical company B], which both implemented reverse stock splits to regain compliance.
• The success rate of companies regaining compliance after receiving a delisting notice varies, with some successfully implementing strategies to increase their share price and others ultimately being delisted.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security.
• The company's ability to raise capital and fund its research and development programs could be negatively impacted.

Next Steps

• Leap Therapeutics will monitor its stock price.
• Leap Therapeutics will consider plans for regaining compliance with Nasdaq listing rules.
• Leap Therapeutics may implement a reverse stock split.

Key Dates